Rifalazil

The first antibiotic of the ansamycin family, rifampicin (RIF), was isolated in 1959 and was introduced into therapy in 1962; it… Expand

 

The incidence and severity of Clostridium difficile-associated disease (CDAD) is increasing, and standard treatment is not always… Expand

OBJECTIVES To determine the safety and effectiveness of single-dose rifalazil, a new rifamycin, for the treatment of… Expand

Although rifamycins have excellent activity against Chlamydophila pneumoniae and Chlamydia trachomatis in vitro, concerns about… Expand

Although vancomycin and metronidazole effectively treat Clostridium difficile-associated diarrhea and colitis (CDAD), their use… Expand

Rifalazil represents a new generation of ansamycins that contain a unique four-ring structure. Originally rifalazil was developed… Expand

Rifalazil, also known as KRM-1648 or benzoxazinorifamycin, is a new semisynthetic rifamycin with a long half-life of… Expand

Rifalazil (formerly known as KRM-1648) in combination with isoniazid has been found to be more active than rifampin/isoniazid… Expand

1. The effect of a new rifamycin derivative, rifalazil (KRM-1648), on liver microsomal enzyme induction was studied in rat and… Expand